1. Home
  2. SFNC vs AGIO Comparison

SFNC vs AGIO Comparison

Compare SFNC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SFNC
  • AGIO
  • Stock Information
  • Founded
  • SFNC 1903
  • AGIO 2007
  • Country
  • SFNC United States
  • AGIO United States
  • Employees
  • SFNC N/A
  • AGIO N/A
  • Industry
  • SFNC Major Banks
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SFNC Finance
  • AGIO Health Care
  • Exchange
  • SFNC Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • SFNC 2.8B
  • AGIO 2.4B
  • IPO Year
  • SFNC N/A
  • AGIO 2013
  • Fundamental
  • Price
  • SFNC $17.95
  • AGIO $43.21
  • Analyst Decision
  • SFNC Hold
  • AGIO Strong Buy
  • Analyst Count
  • SFNC 3
  • AGIO 4
  • Target Price
  • SFNC $23.00
  • AGIO $59.33
  • AVG Volume (30 Days)
  • SFNC 1.1M
  • AGIO 553.8K
  • Earning Date
  • SFNC 10-16-2025
  • AGIO 10-30-2025
  • Dividend Yield
  • SFNC 4.73%
  • AGIO N/A
  • EPS Growth
  • SFNC N/A
  • AGIO N/A
  • EPS
  • SFNC N/A
  • AGIO 11.13
  • Revenue
  • SFNC N/A
  • AGIO $40,875,000.00
  • Revenue This Year
  • SFNC $26.29
  • AGIO $23.76
  • Revenue Next Year
  • SFNC $8.20
  • AGIO $148.23
  • P/E Ratio
  • SFNC N/A
  • AGIO $3.86
  • Revenue Growth
  • SFNC N/A
  • AGIO 30.57
  • 52 Week Low
  • SFNC $17.20
  • AGIO $23.42
  • 52 Week High
  • SFNC $25.95
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • SFNC 33.69
  • AGIO 66.64
  • Support Level
  • SFNC $17.26
  • AGIO $39.71
  • Resistance Level
  • SFNC $18.56
  • AGIO $43.69
  • Average True Range (ATR)
  • SFNC 0.56
  • AGIO 1.43
  • MACD
  • SFNC -0.11
  • AGIO 0.15
  • Stochastic Oscillator
  • SFNC 27.85
  • AGIO 89.02

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: